Navamedic Asa · OSL:NAVA
Navamedic Asa — Q4 2024 Earnings Presentation
21 slides from Navamedic Asa's earnings presentation, Feb 12, 2025
Slide 1: Q4 and full year 2024
Q4 and full year 2024 Highlights and key figures 12 February 2025 Kathrine Gamborg Andreassen, CEO Lars Hjarrand. CFO
Slide 2: Navamedic in brief
Navamedic in brief A reliable supplier of high-quality pharma products addressing global health challenges Presence and sales Strong local market Portfolio tailored for Ambitious growth across the Nordics competence growing markets strategy going forward Strong local competence Thorough understandin
Slide 3: A quarter reflecting investments in growth initiatives
A quarter reflecting investments in growth Highlights Q4 initiatives • Mysimba® 8% growth • 38% growth for Consumer Health • Decreased gross margin and EBITDA impacted by new REVENUE GROSS MARGIN EBITDA growth initiatives and one-offs • Successful launch of Eroxon® in Q4 Finland 131.2 MNOK 33.7 % -3
Slide 4: Continued growth in a year with investments in new growth initiatives
Continued growth in a year with investments in new growth initiatives +4% 500 400 100 Revenue growth and EBITDA NOK million NOK million fluctuations from quarter to 300 quarter mainly due to seasonality and stock build- 200 50 up/down effects 100 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2
Slide 5: High-quality portfolio with several hero products
High-quality portfolio with several hero products Prescription Drugs (RX) Consumer Health Hospital Sold through pharmacies Sold through pharmacies Antibiotics and Medical nutrition* FY 2024 FY 2024 112.5 revenue in revenue in 265.1 MNOK FY 2024 MNOK 131.1 revenue in YoY growth MNOK YoY growth YoY ch
Slide 6: Prescription Drugs (RX)
Prescription Drugs (RX) MYSIMBA® WHOLESALER VOLUME Growth in Mysimba in the quarter, but overall Vol. (units 000) decrease in the RX area 200 150 Q4 2024 revenue 100 69.4 MNOK 50 0 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 (Q4 2023: 73.0 MNOK) 21 22 22 22 22 23 23 23 23 24 24 24 24 Iqvia data; Norway,
Slide 7: How can we reverse the obesity crisis?
Obesity How can we reverse the obesity crisis? In January, Navamedic hosted an event in Norway bringing together a panel of experts to discuss what can be done to reverse the obesity crisis. The discussion included a research report by Opinion, a polling research company, ordered by Navamedic. The r
Slide 8: On track with commercialisation of Flexilev in OraFID
Parkinson’s disease (PD) On track with commercialisation of Flexilev® in OraFID Commercial status Status regulatory FlexiLev®: • License & Supply Agreement signed with Orion Corporation in 2024 for the right to Approved in Sweden, Norway, market and sell Flexilev® in the OraFID container across Euro
Slide 9: Consumer Health
Consumer Health Double-digit growth Year-over-Year The Consumer Health segment comprises Navamedic’s over-the- counter products, available to patients without a prescription Q4 2024 revenue 33.5 MNOK (Q4 2023: 24.2 MNOK) Highlights Coming up next Modifast continues to deliver strong sales with 21% g
Slide 10: Hospital
Hospital Continued solid performance across the segment The Hospital segment comprises Navamedic’s antibiotics portfolio and medical nutrition products for the treatment of Inborn Errors of Metabolism (IEM) Q4 2024 revenue 28.3 MNOK (Q4 2023: 28.0 MNOK) Highlights Coming up next The Medical Nutritio
Slide 11: Delivering on our strategy for becoming a NOK 1 billion revenue company
Delivering on our strategy for becoming a NOK 1 billion revenue company GROWTH BASED ON A STRONG FOUNDATION 1 Untapping the potential within existing products, categories and territories. Strengthening the core with a disciplined approach to portfolio management, including adding attractive new prod
Slide 12: Financials
FINANCIALS @ Navamedic
Slide 13: Key consolidated profit and loss figures
In Q4 2024 revenues were 4.7% above Financials Q4 last year and 3.8% above last year for the full year Key consolidated profit and loss figures Gross Profit came in at 33.7% for the quarter. The low margin was the result of one-offs related to scrap, catch-up of rebates and other items. Excluding th
Slide 14: Assets
Financials Assets (in NOK '1000) 31.12.2024 31.12.2023 Inventory has decreased in line with Goodwill 159 051 156 729 our expectations Deferred tax assets 934 930 Other intangible assets 92 561 97 627 Cash level is mostly the combination of the net result and Property, plant and equipment 4 493 3 692
Slide 15: Equity and liabilities
Financials Equity and liabilities (in NOK '1000) 31.12.24 31.12.23 Total equity 240 437 222 391 Equity ratio of 48.9%% Non-current interest-bearing borrowings 78 571 95 479 Total loans and borrowings is Non-current license liabilities 21 360 3 988 significantly down compared to last Non-current righ
Slide 16: Cash flow Group – total operations
Financials Cash flow Group – total operations The cash flow from Operating (in NOK '1000) Q4 2024 Q4 2023 FY 2024 FY 2023 Activities is mainly the result of Net profit coupled with changes in Net cash flow from operating activities 3 735 -25 348 38 358 2 179 working capital items Net cash flow from
Slide 17: Navamedic ASA summary and outlook
Navamedic ASA summary and outlook A year preparing for new growth opportunities • Navamedic delivered NOK 531.3 million in revenue in 2024, representing a +3.8 Ambition of building a 3.8 % increase from 2023 • The growth in 2024 has been driven by strong growth in Consumer Health and NOK 1 billion H
Slide 18: @ Navamedic
@ Navamedic
Slide 19: Want to know more?
Want to know more? Visit our website https://navamedic.com/ Follow us on LinkedIn #InvestInNavamedic Email infono@navamedic.com Navamedic’s Q1 2025 presentation will be held on 30 April 2025
Slide 20: Basis for preparation
Appendix Basis for preparation This presentation provides financial highlights for the quarter for Navamedic Group. The financial information is not reported according to the requirements in IAS 34 (Interim Financial Reporting) and the figures are not audited. The same measurement principles as pres
Slide 21: Copyright and disclaimer
Appendix Copyright and disclaimer Copyright Copyright of all published material including photographs, drawings and images in this document remains vested in Navamedic and third-party contributors as appropriate. Accordingly, neither the whole nor any part of this document shall be reproduced in any